PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).

Nizar M. Tannir,Neeraj Agarwal,Sumanta K. Pal,Daniel C. Cho,Maria Nirvana Formiga,Jun Guo,Daniel J. George,Mary Tagliaferri,Stina M. Singel,Bridget O'Keeffe,Alison L. Hannah,Minna Balbas,Konstantin Penkov

PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).

2020

Nizar M. Tannir
Neeraj Agarwal
Sumanta K. Pal
Daniel C. Cho
Maria Nirvana Formiga
Jun Guo
Daniel J. George
Mary Tagliaferri
Stina M. Singel
Bridget O'Keeffe
Alison L. Hannah
Minna Balbas
Konstantin Penkov

TPS763Background: Bempegaldesleukin (BEMPEG; NKTR-214) is a first-in-class interleukin-2 (IL-2) receptor pathway agonist that activates and expands effector T cells and natural killer cells in the ...

Keywords:

Cancer research
Pathology
Nivolumab
Agonist
Receptor
Cabozantinib
Renal cell carcinoma
Effector
Medicine
Sunitinib
in patient
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations